English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: The study was aimed to evaluate the effect of Ranolazine on Fasting Plasma Glucose (FPG) in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy. Material & Methods: An open-labeled, randomized, controlled parallel group study was conducted in 76 diagnosed patients of Type –II Diabetes Mellitus with Stable Angina at S.N. medical College and Hospital, Agra. The selected patients randomly assigned into 2 groups, Control group (Group 1): was on their regular therapy during the 8-week study period. Test group (Group 2): was on Ranolazine 500mg BD (orally) in addition to their regular therapy during the 8week study period. The FPG measurement was done at baseline, repeated after 4weeks and at the end of treatment (i.e at 8week). All data obtained were expressed as mean ± standard deviation (SD). Results: In group I Fasting Plasma Glucose (FPG) concentration was 139.59 ± 8.96 mg/dl at 0 week, 138.82 ± 8.76 at 4 week and 139.76 ± 8.87 at the end of 8 week, whereas for group II, it was 140.86 ± 14.70 at 0 week, 137.89 ± 10.25 at 4 week and 134.84 ± 8.42 at the end of 8 week. There was decrease in FPG in Group II and this decrease were statistically significant with P value < 0.05 in comparison to group I at end of 8 week after treatment. Conclusion: Ranolazine significantly reduced FPG in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy in addition to their regular therapy.

To evaluate the effect of Ranolazine on Fasting Plasma Glucose in patients of Type –II Diabetes Mellitus with Stable Angina as add on therapy